1 min read
NervGen Pharma’s Net Loss Rises 36% to C$6.4 Million
Research and development expenses rose 84% to C$7.9 million, while general and administrative expenses increased 154% to C$3.3 million.

NervGen Pharma Corp. (NGEN) posted a C$6.4 million net loss, up 36% year over year, alongside sharp increases in research and administrative expenses, while diluted loss per share fell to C$0.06.
Research and development expenses climbed 84% to C$7.9 million. General and administrative expenses increased 154% to C$3.3 million.
Diluted loss per share was C$0.06, compared with C$0.07 a year earlier.